AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03048851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRCIT group
Description: The participants were randomly assigned to one of the five intervention groups. VRCIT group received the VRCIT training plus traditional rehabilitation, conducted twice per week for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, plus home program, and restraint of the less affected UE for 1.5 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training. The VRCIT combined CIT and commercially available VR-based systems including Sony Playstation EyeToy and Nintendo Wii.
Study NCT03048851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRCIT+SES group
Description: The participants were randomly assigned to one of the five intervention groups. VRCIT+SES group executed VR programs by affected UE in Mesh-gloves (Electro-Mesh Glove-Sleeve Electrode Kit) with the optimal SES (Micro-Z Mini, Prizm Medical Inc., USA) protocol formulated from the 1st phase study. The VRCIT program was conducted 1.5 hours/time, twice/week for 12 weeks. The VRCIT combined CIT and commercially available VR-based systems. Some commercially programs, such as Sony Playstation EyeToy (Sony Computer Entertainment America, Foster City, Calif., USA), and Nintendo Wii (Nintendo Domestic Distributor, College Point, N.Y., USA).
Study NCT03048851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation program
Description: The participants were randomly assigned to one of the five intervention groups. The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
Study NCT00361543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene hydrochloride
Description: 120 mg per capsule (1 tablet daily)
Study NCT00361543 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Capsules
Description: 1 tablet daily for 12 weeks
Study NCT03382496 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT02010840 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation program
Study NCT02010840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation program
Study NCT01638910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027)
Description: Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
Study NCT03159897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.
Study NCT03159897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.
Study NCT03159897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.
Study NCT03159897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.
Study NCT04224155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista MX60EFH trifocal intraocular lenses (IOLs)
Description: enVista MX60EFH trifocal intraocular lenses (IOLs) implanted bilaterally
Study NCT04224155 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enVista MX60E monofocal intraocular lenses (IOLs)
Description: enVista MX60E monofocal intraocular lenses (IOLs) implanted bilaterally
Study NCT05610878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured ASCs enrichment fat grafting
Description: Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs and grafted into recipient site with 1,00,000 cells/ml injected fat
Study NCT05610878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Curcumin-preconditioned ASCs enrichment fat grafting
Description: Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs preconditioned with curcumin and grafted into recipient site with 1,00,000 cells/ml injected fat
Study NCT05610878 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fat grafting
Description: Patients will undergo conventional fat harvesting and grafting of fat into recipient site
Study NCT02868788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fiber
Description: Fiber one supplement (32 grams of fiber) will be consumed with 910 Calorie HFHC meal
Study NCT02868788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFHC meal
Description: 910 Calorie HFHC meal
Study NCT02868788 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HFHC meal
Description: 910 Calorie HFHC meal
Study NCT04491136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI/ARB
Description: Oral ACE/ARB drug according to the investigator's discretion for the first 6 months in this study
Study NCT04491136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARNI
Description: Oral sacubitril/valsartan at the dosage of investigators discretion, whit a target dose of 200mg bid for the next 6 months of this study
Study NCT02056873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous DBS
Description: The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~The DBS system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for DBS. At 6 months, the investigators will determine whether or not the subject is a candidate for responsive brain stimulation (RBS). Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. Subjects who do not qualify or do not participate will continue to receive this intervention for the duration of the study. These subjects will been seen every 6 months for evaluation as part of normal clinical care for DBS.
Study NCT02056873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Responsive Brain Stimulation (RBS Setting)
Description: The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~Six months post-surgery, the DBS system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for DBS.~Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
Study NCT03829072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking Education
Description: cooking Education and adapted physical activity on patients after allo stem cell transplantation
Study NCT03829072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted physical activity
Description: cooking Education and adapted physical activity on patients after allo stem cell transplantation
Study NCT03329547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime test capsule
Description: SKF101804/cefixime test capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as a dark purple head and off white body locking type capsule with GSK' printed on cap and 400MG printed on body of capsule.
Study NCT03329547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime reference capsule
Description: Cefixime reference capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as red/orange hard gelatin size 0 capsule with Cefspan 400 mg printed on body of capsule.
Study NCT03787719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Twice per week dialysis
Description: Twice-weekly 4 hour dialysis treatment
Study NCT02878590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BONGO DEVICE
Description: A device to be used for the treatment of mild to moderate obstructive sleep apnea
Study NCT05460351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BRJ+Nitrate
Description: Participants in this group drank a 70 mL bottle of Beet It Sport drink with nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program
Study NCT05460351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants in this group drank a 70 mL bottle of Beet It Sport drink without nitrate plus 15 grams of whey protein 3 days a week following a resistance exercise training program
Study NCT03446027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NMES
Description: NMES device to be used for up to 3 hours daily in 30 minute sessions for 3 months.
Study NCT02573181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 contains 2 µg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F, and 4 μg of serotype 6B; and 30 µg of CRM₁₉₇ and 125 µg of Aluminum Phosphate Adjuvant (APA) per 0.5 mL dose.
Study NCT02573181 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Prevnar 13™ contains 2.2 μg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4.4 μg of serotype 6B; and 34 μg of CRM₁₉₇ and 125 μg of aluminum per 0.5mL dose.
Study NCT00485251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hand-assisted laparoscopic right hemicolectomy
Description: using the lap disc that allows the insertion of single and into the abdomen for operation
Study NCT00485251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total laparoscopic right hemicolectomy
Description: using laparoscopic instruments for mobilization and dissection inside the abdomen
Study NCT00485251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hand-assisted right hemicolectomy
Description: hand-assisted right hemicolectomy
Study NCT00485251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic right hemicolectomy
Description: using laparoscopic instruments for mobilization and dissection inside the abdomen
Study NCT03681548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation
Study NCT03681548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: 50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation
Study NCT03401398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone, sodium succinate
Description: Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.
Study NCT03401398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
Study NCT00070499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT00070499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO
Study NCT00070499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01169337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Observation
Description: Undergo observation
Study NCT01169337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01169337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01169337 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04297683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: Drug: ABBV-CLS-7162~Administration: Oral~Dose: Dose 1 or Dose 2
Study NCT04297683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Drug: DNL343~Administration: Oral~Dose: Once per day
Study NCT03737149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mymobility with Apple Watch
Description: The mymobility mobile application is a mobile software platform designed to facilitate remote episode of care management and asynchronous communication between the provider care team and their patient via provider-approved care plans and engagement communications. Current care pathways have been developed for: Total Hip Replacement, Total Knee Replacement and Partial Knee Replacement. Designed for the orthopedic population, mymobility also integrates wearable data from the Apple Watch into provider dashboards, providing enhanced understanding and monitoring of patients throughout the episode of care.
Study NCT03272373 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NexGen TM Monoblock Tibia
Description: Primary cementless tibia total knee arthroplasty
Study NCT04027491 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session.~The intervention treatment consists of 12 sessions in 4-week period.
Study NCT03272373 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NexGen TM Modular Tibia
Description: Primary cementless tibia total knee arthroplasty
Study NCT03250975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide and Azithromycin
Description: Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
Study NCT03250975 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control of budesonide and azithromycin
Description: placebos of the medications will be given for 14 days in patients randomized to the control group
Study NCT02104310 — intervention group
Intervention type: DRUG
Intervention: Fluorine-18-L-dihydroxyphenylalanine
Description: 5 millicuries ± 10%; Intravenous injection; 1 time
Study NCT01112488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Engagement Programme
Description: Patient's Diary, Ad Hoc medical support and Ad Hoc Clinical admission, Early post discharge Home visit
Study NCT03991923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XVIVO heart preservation devices
Description: The intervention is to preserve hearts during transportation cold, cardioplegic and non-ischemic, with a high oncotic and hormone supplemented perfusate.
Study NCT03991923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ICSS
Description: Cold static preservation using standard preservation solution
Study NCT04010760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Test of biomarkers for PE in EBC
Description: New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath condensate (EBC).~The EBC will be collected by use of the RTube(R) system which has been used in previous studies of EBC. As the patient breathes through a mouth piece, the exhaled breath is led through a cooling chamber where the vaporous part of the exhaled breath condenses.~We aim at collecting a total minimum of 3.0 mL EBC per study subject in order to have a sufficient amount of protein for the subsequent analysis. We aim at collecting exhaled breath condensate for 2\*15 minutes with the possibility to stop the collection after less than 15 minutes if the volume is sufficient.
Study NCT03594448 — intervention group
Intervention type: PROCEDURE
Intervention: Specimen Collection
Description: Undergo collection of blood samples
Study NCT03594448 — intervention group
Intervention type: PROCEDURE
Intervention: Serial Liquid Biopsy
Description: Undergo serial liquid biopsy
Study NCT03444064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PolyTregs
Description: Treatment group receive PolyTregs 6 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
Study NCT03448354 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: HIPEC(paclitaxel 175mg/m2, 90min; open or closed technique) after IDS . IDS is recommended within 4 weeks after the 3rd NAC cycle. HIPEC procedure is allowed only in case of residual disease less than 5mm.
Study NCT01052870 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Finasteride
Description: Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
Study NCT01052870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
Study NCT01730118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine
Description: autologous AdHER2 transduced dendritic cell vaccine manufactured under Good Manufacturing Practices (GMP) conditions from cryopreserved patient monocytes here at the National Institutes of Health (NIH) Clinical Center (CC) Department of Transfusion Medicine (DTM). Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.
Study NCT03051529 — intervention group
Intervention type: OTHER
Intervention: combined spinal epidural anesthesia
Description: After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
Study NCT01868516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmecamylamine
Study NCT01868516 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01857362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone 20 mg
Description: Nitisinone 20 mg capsules
Study NCT01857362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitisinone 10 mg
Description: Nitisinone 10 mg capsules
Study NCT04759118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified childbirth education program
Description: The participants in the intervention group are pregnant women and their husbands. The instructors employed teaching methods such as a group discussion, watching videos, and brainstorming, as well as questions and answer periods, demonstrations, childbirth simulation, and practice. The primary investigator (PI) will teach particular sessions, including maternal-fetal attachment skills, parenting skills, comfort measures, childbirth positions, as well as knowledge about anatomy and physiology during pregnancy and birth Classes consisted of 120-minute sessions held once a week for four weeks.
Study NCT04163185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-07 (MoSEIC meloxicam and rizatriptan)
Description: AXS-07 tablet taken once upon the earliest onset of migraine pain.
Study NCT04163185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken once upon the earliest onset of migraine pain.
Study NCT01905371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Study NCT01905371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.